HIV 1 News and Research

RSS

Grant awarded for research into a new treatment for methamphetamine addiction

Dr. Keith Flower - a research physician at the Addiction Pharmacology & Research Laboratory in San Francisco, CA - has been awarded a grant to investigate a new medication treatment for methamphetamine addiction. This grant has been awarded to California Pacific Medical Center's Research Institute through President Obama's AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009.

6 Nov 2009

Gene therapy saves two children with adrenoleukodystrophy

The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases.

6 Nov 2009

UCSF HIV researchers receive two NIH grants to improve health of HIV positive patients

UCSF HIV researchers have received two NIH grants of $1 million each to study the use of web-based, patient controlled personal health records to improve health and HIV prevention outcomes for HIV positive patients.

6 Nov 2009

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

6 Nov 2009

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

5 Nov 2009

MSF calls for sustained commitment to global HIV/AIDS funding

During a press conference on Thursday, Medecins Sans Frontieres (MSF) warned that the "global economic crisis and calls to commit funds to other health crises" threatened to undermine recent gains in the fight against HIV/AIDS, the Associated Press reports. MSF "says money for other health issues should be given in addition to money for [HIV/]AIDS" (11/5).

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Mandatory minimum sentences for drug-related offences, an ineffective approach

Mandatory minimum sentences for drug-related offences are an expensive and ineffective approach to substance use problems in Canada. That's the message being delivered today by an addictions professional at Canada's largest mental health and addictions treatment and research hospital to a Senate Committee on Bill C-15 - legislation that would create mandatory minimum sentences for certain drug-related offences.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

PEPFAR expands efforts to improve health services worldwide through use of mobile devices

Fierce Mobile reports on the recent announcement that PEPFAR is teaming up with the United Nations Foundation, Rockefeller Foundation and Vodafone Foundation to be a founding member of the mHealth Alliance, "a group seeking to bring health services to the most remote corners of the globe using mobile networks and technologies." U.S. Global AIDS Coordinator Eric Goosby announced the partnership during a keynote address last week at the inaugural mHealth Summit in Washington, D.C., according to the news service (Versel, 11/3).

4 Nov 2009

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).

4 Nov 2009

AMFm subsidized malaria drugs to be delivered soon

Subsidized artemisinin-based combination therapies (ACTs) under the Affordable Medicines Facility - malaria (AMFm) program will be available in select countries "in two week's time," SABC News reports. The announcement came Monday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya.

4 Nov 2009

PAH patients face life-threatening risks from medication errors

Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists.

4 Nov 2009

Leprosy: Man's persistent companion

For thousands of years an undesirable and persistent companion has been travelling with man wherever he goes. Mycobacterium leprae, the bacterium that causes leprosy, has only one known natural host - mankind.

4 Nov 2009

Kaiser Permanente to host 2009 National Diversity Conference in San Francisco

Kaiser Permanente will host its 2009 National Diversity Conference November 4-6 at the Palace Hotel in San Francisco.

4 Nov 2009

Experts team up to measure the hearing of people with AIDS

Specialists in HIV and in hearing at the University of Rochester Medical Center are teaming up to measure the hearing of people with AIDS.

4 Nov 2009

R&D of HIV treatments at crossroads

IP Overview HIV Therapy 2009” ( www.frinnov.fr/en/ip-overview/sciences-de-la-vie/hiv-therapy-2.html ) establishes a panorama of the patents claiming “HIV and AIDS treatments” and analyses the key and emerging thematic and the strategic positions of the actors involved in this sector. In order to fully analyze this field, the information coming from 6800 published patents and patent applications was aggregated.

4 Nov 2009

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer on Tuesday formally launched ViiV Healthcare, a company focused on the development of new HIV treatments, Dow Jones Newswires/SmartMoney.com reports (11/3).

3 Nov 2009

Health affairs issue focuses on HIV/AIDS, NTDs

By 2031 developing countries could need an estimated $35 billion to fight HIV/AIDS - three times the amount currently spent, according to a Health Affairs study published Tuesday, the New York Times reports.

3 Nov 2009

Also in Global Health News: Breast cancer in developing world; Burkina Faso ITN distribution; diarrhea in people over age five; Gates Q&A

"International cancer specialists meet this week to plan an assault on a troubling increase of breast cancer in developing countries, where nearly two-thirds of women aren't diagnosed until it has spread through their bodies," the Associated Press reports. Researchers will also look at "some worrisome data" that suggests breast cancer affects "women, on average, about 10 years" earlier in developing countries than it does in the U.S. (Neergaard, 11/3).

3 Nov 2009